Table 1 Univariate and multivariable analysis of factors associated with use of RS testing

From: Use of 21-gene recurrence score assay to individualize adjuvant chemotherapy recommendations in ER+/HER2− node positive breast cancer—A National Cancer Database study

  

RS testing

Univariate

Multivariable

Variable

Total N = 72,897 N (%)

No N = 57,869 N (%)

Yes N = 15,028 N (%)

Odds Ratio (95% CI)

P-value

Odds Ratio (95% CI)

P-value

Age category

    

Overall trend p < 0.001

 

Overall trend p = 0.35

<40

4052 (5.6%)

3601 (88.9%)

451 (11.1%)

0.45 (0.41, 0.50)

<0.001

0.63 (0.56, 0.71)

<0.001

40–49

14,727 (20.2%)

12,042 (81.8%)

2685 (18.2%)

0.80 (0.76, 0.85)

<0.001

0.79 (0.74, 0.83)

<0.001

50–59

19,858 (27.2%)

15,547 (78.3%)

4311 (21.7%)

1.0 reference

 

1.0 reference

 

60–69

18,889 (25.9%)

14,104 (74.7%)

4785 (25.3%)

1.22 (1.17, 1.28)

<0.001

1.23 (1.17, 1.30)

<0.001

70–79

10,554 (14.5%)

8086 (76.6%)

2468 (23.4%)

1.10 (1.04, 1.16)

<0.001

1.12 (1.04, 1.21)

0.003

80+

4817 (6.6%)

4489 (93.2%)

328 (6.8%)

0.26 (0.23, 0.30)

<0.001

0.27 (0.24, 0.31)

<0.001

Race

       

Black

7856 (10.8%)

6583 (83.8%)

1273 (16.2%)

0.71 (0.67, 0.76)

<0.001

0.81 (0.76, 0.87)

<0.001

Other/unknown

3615 (5.0%)

2939 (81.3%)

676 (18.7%)

0.85 (0.78, 0.93)

<0.001

0.88 (0.80, 0.96)

0.005

White

61,426 (84.3%)

48,347 (78.7%)

13,079 (21.3%)

1.0 reference

 

1.0 reference

 

Charlson–Deyo score

    

Overall trend p < 0.001

 

Overall trend p = 0.12

0

60,427 (82.9%)

47,783 (79.1%)

12,644 (20.9%)

1.0 reference

 

1.0 reference

 

1

10,205 (14.0%)

8233 (80.7%)

1972 (19.3%)

0.91 (0.86, 0.95)

<0.001

0.93 (0.87, 0.98)

0.01

2+

2265 (3.1%)

1853 (81.8%)

412 (18.2%)

0.84 (0.75, 0.94)

<0.001

0.91 (0.80, 1.02)

0.10

Primary payor

       

Private insurance/managed care

40,912 (56.1%)

32,046 (78.3%)

8866 (21.7%)

1.0 reference

 

1.0 reference

 

Medicaid/ not insured

7542 (10.3%)

6402 (84.9%)

1140 (15.1%)

0.64 (0.60, 0.69)

<0.001

0.77 (0.72, 0.83)

<0.001

Medicare

22,729 (31.2%)

18,037 (79.4%)

4692 (20.6%)

0.94 (0.90, 0.98)

0.002

0.97 (0.92, 1.03)

0.35

Other government

863 (1.2%)

701 (81.2%)

162 (18.8%)

0.84 (0.70, 0.99)

0.04

0.88 (0.73, 1.06)

0.19

Insurance status unknown

851 (1.2%)

683 (80.3%)

168 (19.7%)

0.89 (0.75, 1.05)

0.18

0.93 (0.77, 1.11)

0.41

Year of diagnosis

    

Overall trend p < 0.001

 

Overall trend p < 0.001

2010

16,819 (23.1%)

14,301 (85.0%)

2518 (15.0%)

1.0 reference

 

1.0 reference

 

2011

18,496 (25.4%)

14,886 (80.5%)

3610 (19.5%)

1.38 (1.30, 1.46)

<0.001

1.39 (1.31, 1.47)

<0.001

2012

18,779 (25.8%)

14,482 (77.1%)

4297 (22.9%)

1.69 (1.60, 1.78)

<0.001

1.74 (1.64, 1.85)

<0.001

2013

18,803 (25.8%)

14,200 (75.5%)

4603 (24.5%)

1.84 (1.74, 1.94)

<0.001

1.91 (1.80, 2.02)

<0.001

Facility type

       

Comprehensive community cancer program

34,845 (47.8%)

27,622 (79.3%)

7223 (20.7%)

1.20 (1.13, 1.28)

<0.001

1.16 (1.09, 1.25)

<0.001

Academic/research program

21,024 (28.8%)

16,101 (76.6%)

4923 (23.4%)

1.41 (1.32, 1.50)

<0.001

1.41 (1.31, 1.51)

<0.001

Integrated network cancer program/other

5149 (7.1%)

4115 (79.9%)

1034 (20.1%)

1.16 (1.06, 1.26)

0.001

1.08 (0.98, 1.19)

0.13

Facility type unknown

4052 (5.6%)

3601 (88.9%)

451 (11.1%)

0.58 (0.51, 0.65)

<0.001

–

–

Community cancer program

7827 (10.7%)

6430 (82.2%)

1397 (17.8%)

1.0 reference

 

1.0 reference

 

Pathologic T stage

    

Overall Trend p < 0.001

 

Overall Trend p < 0.001

T1

32,178 (44.1%)

22,860 (71.0%)

9318 (29.0%)

1.0 reference

 

1.0 reference

 

T2

32,714 (44.9%)

27,470 (84.0%)

5244 (16.0%)

0.47 (0.45, 0.49)

<0.001

0.67 (0.65, 0.70)

<0.001

T3/T4 a-c

8005 (11.0%)

7539 (94.2%)

466 (5.8%)

0.15 (0.14, 0.17)

<0.001

0.30 (0.27, 0.34)

<0.001

Pathologic N stage

    

Overall Trend p < 0.001

 

Overall Trend p < 0.001

N1mi

10,773 (14.8%)

6068 (56.3%)

4705 (43.7%)

1.0 reference

 

1.0 reference

 

N1

44,126 (60.5%)

34,391 (77.9%)

9735 (22.1%)

0.37 (0.35, 0.38)

<0.001

0.40 (0.38, 0.42)

<0.001

N2+

17,998 (24.7%)

17,410 (96.7%)

588 (3.3%)

0.04 (0.04, 0.05)

<0.001

0.06 (0.05, 0.06)

<0.001

Grade

    

Overall Trend p < 0.001

 

Overall Trend p < 0.001

Well differentiated

13,127 (18.0%)

9306 (70.9%)

3821 (29.1%)

1.0 reference

 

1.0 reference

 

Moderately differentiated

37,892 (52.0%)

29,687 (78.3%)

8205 (21.7%)

0.67 (0.64, 0.70)

<0.001

0.83 (0.79, 0.87)

<0.001

Poorly differentiated/Undifferentiated

18,037 (24.7%)

15,756 (87.4%)

2281 (12.6%)

0.35 (0.33, 0.37)

<0.001

0.54 (0.50, 0.57)

<0.001

Cell type undetermined

3841 (5.3%)

3120 (81.2%)

721 (18.8%)

0.56 (0.51, 0.62)

<0.001

0.67 (0.61, 0.74)

<0.001

ILC histology

       

Yes

10,265 (14.1%)

8441 (82.2%)

1824 (17.8%)

1.0 reference

 

1.0 reference

 

No

62,632 (85.9%)

49,428 (78.9%)

13,204 (21.1%)

1.24 (1.17, 1.30)

<0.001

0.94 (0.88, 1.0)

0.035

Progesterone receptor (PR) status

       

Negative

7396 (10.1%)

6302 (85.2%)

1094 (14.8%)

1.0 reference

 

1.0 reference

 

Positive

65,390 (89.7%)

51,473 (78.7%)

13,917 (21.3%)

1.56 (1.46, 1.67)

<0.001

1.27 (1.18, 1.37)

<0.001

Unknown

111 (0.2%)

94 (84.7%)

17 (15.3%)

1.04 (0.62, 1.75)

<0.001

1.0 (0.57, 1.76)

>0.99

Back to article page